KRAS Oncogene Connect
  • Saved

4yr

KRAS-targeted therapies in advanced solid cancers: drug the undruggable? - PubMed

KRAS-targeted therapies in advanced solid cancers: drug the undruggable? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34148378/

1 Department of Hematology, Gustave Roussy Cancer Campus, Villejuif, 94800, France. 2 Department of Pathology, National Institute of Pathology, Baabda, 1003, Lebanon. 3 Department of Radiation Oncology, Hotel-Dieu de France...

  • Saved

4yr

Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics - PubMed

Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34347509/

Introduction: KRAS is the most frequently mutated oncogenic driver in pancreatic, lung, and colon cancer. Recently, KRAS inhibitors in clinical use show promising activity but most responses are partial and...

  • Saved

4yr

KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms - PubMed

KRAS inhibitor-resistance in MET-amplified KRAS G12C non-small cell lung cancer induced by RAS- and non-RAS-mediated cell signaling mechanisms - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34365406/

doi: 10.1158/1078-0432.CCR-21-0856. Online ahead of print. 1 Department of Medical Oncology, Kindai University Faculty of Medicine. 2 Department of Medical Oncology, Kindai University Faculty of Medicine [email protected]. 3 Division of...

  • Saved

made a Post

5yr

The most commonly mutated oncogene in human cancer is rat sarcoma (RAS), with Kirsten rat sarcoma (KRAS) being the most frequently mutated RAS isoform. In the aggregate, KRAS accounts for 85% of RAS mutations in human cancer, and KRAS exists in 35% of lung adenocarcinomas.



The dysregulation of KRAS results in tumor growth and mediates interactions between cancer cells and the tumor microenvironment, thus impacting therapeutic response. KRAS mutations likely occur early in carcinogenesis and facilitate the survival, invasion, and migration of cancer cells. Smoking has been strongly linked to KRAS mutations in lung cancer.



Previously, KRAS was considered “undruggable” due to difficulty with identifying actionable target-inhibitor binding sites. New developments show that targeting the KRAS 12 glycine to cysteine (G12C) mutation, which depends on covalent modification of the cysteine residue, is effective in the treatment of NSCLC.



What is your experience with KRAS-positive lung cancer? In which patients would you consider KRAS inhibitors?



https://pubmed.ncbi.nlm.nih.gov/34089836/



https://pubmed.ncbi.nlm.nih.gov/34151545/


  • 5yr
    KRAS is a common mutation in NSCLC. Sotorasib is the first drug approved for targeting the KRAS G12C mutation. I had the opportunity to use this only once so far Show More
  • 5yr
    Only KRAS mutation that is druggable is G12C. Sotorasib recently approved for KRAS G12C patients and has a RR 35% with some CRs.

Show More Comments

  • Saved

made a Post

5yr

The most commonly mutated oncogene in human cancer is rat sarcoma (RAS), with Kirsten rat sarcoma (KRAS) being the most frequently mutated RAS isoform. In the aggregate, KRAS accounts for 85% of RAS mutations in human cancer, and KRAS exists in 35% of lung adenocarcinomas.



The dysregulation of KRAS results in tumor growth and mediates interactions between cancer cells and the tumor microenvironment, thus impacting therapeutic response. KRAS mutations likely occur early in carcinogenesis and facilitate the survival, invasion, and migration of cancer cells. Smoking has been strongly linked to KRAS mutations in lung cancer.



Previously, KRAS was considered “undruggable” due to difficulty with identifying actionable target-inhibitor binding sites. New developments show that targeting the KRAS 12 glycine to cysteine (G12C) mutation, which depends on covalent modification of the cysteine residue, is effective in the treatment of NSCLC.



What is your experience with KRAS-positive lung cancer? In which patients would you consider KRAS inhibitors?



https://pubmed.ncbi.nlm.nih.gov/34089836/



https://pubmed.ncbi.nlm.nih.gov/34151545/


  • 5yr
    KRAS is a common mutation in NSCLC. Sotorasib is the first drug approved for targeting the KRAS G12C mutation. I had the opportunity to use this only once so far Show More
  • 5yr
    Only KRAS mutation that is druggable is G12C. Sotorasib recently approved for KRAS G12C patients and has a RR 35% with some CRs.

Show More Comments